Propanc Health (PPCH) 0.0200 $PPCH
Propanc Raises Capital to Complete Next Round of Animal Studies
PR Newswire - Tue Mar 17, 8:00AM CDT
Propanc Health Group Corporation (OTCPK: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced it has raised $468,500 from institutional investors so far this year, with $532,500 in additional funding commitments. Funds realized from this financing will be used to complete the next phase of animal studies which are pivotal for entry into human trials and initiation of licensing discussions for its lead product, PRP.
Small Biotec Firm Quietly Makes +1,000% Price Move
ACCESSWIRE - Tue Mar 17, 12:26AM CDT
WINDOSR, ON / ACCESSWIRE / March 17, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce a Company mentioned in last week's update has surged amidst growing Investor interest.
VSTM: 10.84 (-0.18), CTIC: 1.91 (-0.03), STML: 15.93 (-0.33)
Penny Stocks Alerts for Axiom, Propanc Health Group, HEAR ATLAST, Pazoo, NIOCORP DEVELOPMENTS, and EASTMAIN RES
PR Newswire - Thu Mar 12, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Axiom (OTCMKTS:AXMM), Propanc Health Group (OTCMKTS
PCH), HEAR ATLAST (OTCMKTS:HRAL), Pazoo (OTCMKTSZOO), NIOCORP DEVELOPMENTS (OTCMKTS:NIOBF), and EASTMAIN RES (OTCMKTS:EANRF).
Propanc Helping to Unravel Mystery Associated with Carcinomas
PR Newswire - Wed Mar 11, 3:00AM CDT
Propanc Health Group Corporation (OTCPK: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced fresh new insights have emerged into the development and spread of carcinomas, published in the British Journal of Cancer by researchers from the University of Glasgow. The findings may have significant implications for Propanc's lead product, PRP, as a new method to control cancer spread, known as metastasis, the main cause of patient death from cancer.
Biotech Company Could Be on the Cusp of New Proenzyme Drug for the Treatment and Prevention of Certain Forms of Cancer
ACCESSWIRE - Mon Mar 09, 3:10PM CDT
WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
VSTM: 10.84 (-0.18), CTIC: 1.91 (-0.03), STML: 15.93 (-0.33)
Oncology Biotech Company Could Be on the Cusp of New PRP Drug for the Treatment and Prevention of Metastatic Cancer
ACCESSWIRE - Mon Mar 09, 9:37AM CDT
WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
BLUE: 120.46 (-1.43), BIIB: 427.93 (+1.81), GILD: 100.28 (-0.16), KITE: 63.52 (-0.13), ARIA: 8.59 (-0.13), CELG: 122.68 (+1.65)
Propanc Announces Latest Company Initiatives
PR Newswire - Tue Jan 13, 8:00AM CST
Propanc Health Group Corporation (OTCPK: PPCH) ("Propanc" or "the Company", an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, today announced a summary of the Company's recent activities that position the company for planned future growth this year.
Bio-Tech Company with Groundbreaking Technology
M2 - Fri Jan 09, 5:39AM CST
Propanc Health Group Corp., a biopharmaceutical company organized in Melbourne, Australia, in 2007, has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasis. Targeted therapies for metastatic cancer has long been regarded as an important goal in cancer research, as metastasis is the cause of most cancer-related deaths and as no currently approved cancer therapies target metastasis.
Propanc enters into $5 million Equity Purchase Agreement with Southridge Partners
PR Newswire - Mon Sep 22, 3:01PM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA" with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms.
Propanc Stock Now DWAC/FAST Eligible
GlobeNewswire - Fri Jul 18, 3:00PM CDT
Propanc Health Group Corporation (OTCQBPCH) ("Propanc" or "the Company", an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients, is pleased to announce that the Depository Trust Corporation (the "DTC" has approved its common stock for DWAC/FAST transfer through the Company's Transfer Agent, V Stock, LLC. This newly approved stock transfer capability will enable Propanc's shareholders to transfer their shares of Propanc stock electronically after buying or selling on the open market, without the extra expense and delay associated with the processing and transfer of physical share certificates.
Propanc Raises Capital to Complete Next Round of Animal Studies
PR Newswire - Tue Mar 17, 8:00AM CDT
Propanc Health Group Corporation (OTCPK: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced it has raised $468,500 from institutional investors so far this year, with $532,500 in additional funding commitments. Funds realized from this financing will be used to complete the next phase of animal studies which are pivotal for entry into human trials and initiation of licensing discussions for its lead product, PRP. Small Biotec Firm Quietly Makes +1,000% Price Move
ACCESSWIRE - Tue Mar 17, 12:26AM CDT
WINDOSR, ON / ACCESSWIRE / March 17, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce a Company mentioned in last week's update has surged amidst growing Investor interest.
VSTM: 10.84 (-0.18), CTIC: 1.91 (-0.03), STML: 15.93 (-0.33)
Penny Stocks Alerts for Axiom, Propanc Health Group, HEAR ATLAST, Pazoo, NIOCORP DEVELOPMENTS, and EASTMAIN RES
PR Newswire - Thu Mar 12, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Axiom (OTCMKTS:AXMM), Propanc Health Group (OTCMKTS
PCH), HEAR ATLAST (OTCMKTS:HRAL), Pazoo (OTCMKTSZOO), NIOCORP DEVELOPMENTS (OTCMKTS:NIOBF), and EASTMAIN RES (OTCMKTS:EANRF). Propanc Helping to Unravel Mystery Associated with Carcinomas
PR Newswire - Wed Mar 11, 3:00AM CDT
Propanc Health Group Corporation (OTCPK: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced fresh new insights have emerged into the development and spread of carcinomas, published in the British Journal of Cancer by researchers from the University of Glasgow. The findings may have significant implications for Propanc's lead product, PRP, as a new method to control cancer spread, known as metastasis, the main cause of patient death from cancer. Biotech Company Could Be on the Cusp of New Proenzyme Drug for the Treatment and Prevention of Certain Forms of Cancer
ACCESSWIRE - Mon Mar 09, 3:10PM CDT
WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
VSTM: 10.84 (-0.18), CTIC: 1.91 (-0.03), STML: 15.93 (-0.33)
Oncology Biotech Company Could Be on the Cusp of New PRP Drug for the Treatment and Prevention of Metastatic Cancer
ACCESSWIRE - Mon Mar 09, 9:37AM CDT
WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
BLUE: 120.46 (-1.43), BIIB: 427.93 (+1.81), GILD: 100.28 (-0.16), KITE: 63.52 (-0.13), ARIA: 8.59 (-0.13), CELG: 122.68 (+1.65)
Propanc Announces Latest Company Initiatives
PR Newswire - Tue Jan 13, 8:00AM CST
Propanc Health Group Corporation (OTCPK: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, today announced a summary of the Company's recent activities that position the company for planned future growth this year. Bio-Tech Company with Groundbreaking Technology
M2 - Fri Jan 09, 5:39AM CST
Propanc Health Group Corp., a biopharmaceutical company organized in Melbourne, Australia, in 2007, has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasis. Targeted therapies for metastatic cancer has long been regarded as an important goal in cancer research, as metastasis is the cause of most cancer-related deaths and as no currently approved cancer therapies target metastasis.
Propanc enters into $5 million Equity Purchase Agreement with Southridge Partners
PR Newswire - Mon Sep 22, 3:01PM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA" with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms. Propanc Stock Now DWAC/FAST Eligible
GlobeNewswire - Fri Jul 18, 3:00PM CDT
Propanc Health Group Corporation (OTCQB
PCH) ("Propanc" or "the Company", an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients, is pleased to announce that the Depository Trust Corporation (the "DTC" has approved its common stock for DWAC/FAST transfer through the Company's Transfer Agent, V Stock, LLC. This newly approved stock transfer capability will enable Propanc's shareholders to transfer their shares of Propanc stock electronically after buying or selling on the open market, without the extra expense and delay associated with the processing and transfer of physical share certificates. 
